MNMatus Niznansky

Matus Niznansky

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Matus Niznansky has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Jaroslav Lindner

    2nd Department of Surgery, Department of Cardiovascular Surgery, First Faculty of Medicine, Charles University and General University Hospital, 128 08 Prague, Czech Republic

    5 shared publications
  • David Ambrož

    2nd Department of Internal Medicine–Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, 128 08 Prague, Czech Republic

    4 shared publications
  • Pavel Jansa

    Charles University and General University Hospital, Prague, Czech Republic

    4 shared publications
  • Vladimir Cerny

    Department of Radiology, First Faculty of Medicine, Charles University and General University Hospital, 128 08 Prague, Czech Republic

    3 shared publications
  • Ales Linhart

    2nd Department of Internal Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital , Prague

    2 shared publications
  • Jan Kunstyr

    Department of Anaesthesiology and Intensive Care Medicine, General University Hospital and First Faculty of Medicine, Charles University in Prague, U Nemocnice 2, Prague 128 08, Czech Republic

    2 shared publications

Latest Publications

  • Open Access

    Correction: Jansa et al. Hospitalisation Is Prognostic of Survival in Chronic Thromboembolic Pulmonary Hypertension. J. Clin. Med. 2022, 11, 6189

    by Pavel Jansa, David Ambrož, Michael Aschermann, Vladimír Černý, Vladimír Dytrych, Samuel Heller, Jan Kunstýř, Jaroslav Lindner, Aleš Linhart, Matúš Nižnanský, et al.


  • Open Access

    Hospitalisation Is Prognostic of Survival in Chronic Thromboembolic Pulmonary Hypertension

    by Pavel Jansa, David Ambrož, Michael Aschermann, Vladimír Černý, Vladimír Dytrych, Samuel Heller, Jan Kunstýř, Jaroslav Lindner, Aleš Linhart, Matúš Nižnanský, et al.

    This analysis investigated the prognostic value of hospitalisation in chronic thromboembolic pulmonary hypertension (CTEPH) using data from the Czech Republic, wherein pulmonary endarterectomy (PEA) was the only targeted treatment option until 2015. Using a landmark method, this analysis quantified the association between a first CTEPH-related hospitalisation event occurring before 3-, 6-, 9-, and 12-month landmark timepoints and subsequent all-cause mortality in adult CTEPH patients diagnosed between 2003 and 2016 in the Czech Republic. Patients were stratified into operable and inoperable, according to PEA eligibility. CTEPH-related hospitalisations were defined as non-elective. Hospitalisations related to CTEPH diagnosis, PEA, balloon pulmonary angioplasty, or clinical trial participation were excluded. Of 436 patients who survived to ≥3 months post diagnosis, 309 were operable, and 127 were inoperable. Sex- and age-adjusted hazard ratios (HRs) showed CTEPH-related hospitalisation was a statistically significant prognostic indicator of mortality at 3, 9, and 12 months in inoperable patients, with an approximately 2-fold increased risk of death in the hospitalisation group (HRs [95% CI] ranging from 1.98 [1.06–3.70] to 2.17 [1.01–4.63]). There was also a trend of worse survival probabilities in the hospitalisation groups for operable patients, with the difference most pronounced at 3 months, with a 76% increased risk of death (adjusted HR [95% CI] 1.76 [1.15–2.68]). This first analysis on the prognostic value of CTEPH-related hospitalisations demonstrates that a first CTEPH-related hospitalisation is prognostic of mortality in CTEPH, particularly for inoperable patients. These patients may benefit from medical and/or interventional therapy.


  • Open Access

    Computed tomography angiographic parameters of pulmonary artery as prognostic factors of residual pulmonary hypertension after pulmonary endarterectomy

    by Matus Niznansky, Jan Kavan, Petra Zemankova, Tomas Prskavec, David Ambroz, Pavel Jansa, Jaroslav Lindner

    Objectives: This study aimed to retrospectively assess using computed tomography pulmonary angiography (CTPA) for predicting residual pulmonary hypertension (RPH) in patients with chronic thromboembolic pulmonary hypertension (CTEPH) after pulmonary endarterectomy (PEA). Methods: We retrospectively analyzed data of 131 patients with CTEPH who underwent PEA in our center (2008–2015). We measured several diameters of the pulmonary artery and thoracic aorta preoperatively. We evaluated the relationship between these measurements (and their indices) and signs of RPH represented by pulmonary artery systolic pressure (PASP) estimated by echocardiography. Results: Significant correlations were observed between the aortopulmonary index and prediction of any residual hypertension and moderate/severe hypertension 1 year after PEA, and any residual hypertension and severe hypertension 2 years after PEA. The aortopulmonary index was significantly related to a reduction in PASP 1 year after the operation. A lower aortopulmonary index (≤0.88 for the ascending aorta and ≤0.64 for the descending aorta) predicted lower RPH. Conclusions: Preoperative CTPA parameters can be used to assess the risk of RPH after PEA. The aortopulmonary index has significant predictive value for RPH and a reduction in PASP after PEA. Lower values of the aortopulmonary index suggest a better outcome after PEA.


  • Open Access

    Chylous pericardial effusion as a rare complication after pulmonary endarterectomy

    by Matus Niznansky, Tomas Prskavec, Vladimir Cerny, Jaroslav Lindner

    Chylous pericardial effusion is a rare complication of cardiac surgery. We report a case of a patient who underwent pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension and was diagnosed with chylopericardium after the procedure. We present the surgical management of this condition, which included bilateral pedal lymphangiography followed by ligation of injured lymph vessel.


  • Pulmonary endarterectomy combined with cardiac surgery: A 7-year retrospective analysis

    by Jaroslav Lindner, David Ambrož, Róbert Novotný, Matúš Nižňanský, Iveta Šimková, Marcela Boháčeková, Ondrej Pecha, Pavel Jansa

    BackgroundPulmonary artery endarterectomy (PEA) is established as a successful method for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH). A significant fraction of patients indicated for the pulmonary endarterectomy has other severe comorbidities that generally increase the risk of cardiac surgery. The aim of our study is to analyze the process of indications and therapeutic procedures at our Cardio-Centre, as well as comparing hemodynamic parameters and long-term results in order to determine the continuation of the treatment.MethodFrom September 2004 to August 2012, 192 patients underwent PEA for CTEPH. We carried out a retrospective analysis of patients’ data. Patients were divided into two groups: A and B. The group A included patients with PEA only (128 patients), group B consisted of patients with PEA and other cardiac procedure (64 patients, i.e. 33.3% of which 72 cardiac procedures were carried out). Group B was further subdivided into group B1-patients with PEA+CABG, which included 25 patients, and group B2-PEA+suture of PFO, which consisted of 29 patients for more detailed analysis.ResultsFive-year survival rate is 83% in group A, 79.3% in group B, and 63.1% in group B1. Group B1 is statistically significantly different from group A (P=0.031). The cumulative survival rate is comparable for groups A and B2. Cumulative survival rate is very good with annual survival in group A – 94%, group B2 – 90% and group B1 – 82.6%.ConclusionResults of combined interventions are comparable with isolated pulmonary endarterectomy. We did not find any differences in hemodynamic effects. All patients indicated for the PEA should be screened for the most common comorbidities regardless of their age. We recommend implementation CryoMAZE for the treatment of atrial fibrillation or atrial flutter